Fresh analysis suggests that people who stop using new slimming jabs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise plans.
Research printed in a major medical journal points out that while obese individuals can lose a large proportion of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments should be informed of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to starting mass within about one and a half years.
Comparing Treatments
The research, which looked at 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with conventional dieting.
The team note that individuals who shed pounds through dieting typically have a less rapid weight regain—perhaps 100 grams monthly—after stopping.
The Reason for the Fast Regain
Experts believe the mechanism of the drugs explains the amplified regain.
These medications mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who note that the findings "highlight the persistent nature of obesity," comparing it to managing conditions like diabetes.
User Accounts
People who have discontinued the jabs explain a intense return of hunger.
"I experienced a trigger flipping and I was suddenly starving," recalled an individual.
This challenge is worsened if users have not developed permanent dietary or behavioural modifications during treatment.
Growing Adoption
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among females compared to males.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while the jabs are powerful tools for weight loss, they are not a permanent cure and long-term success likely depends on integrated lifestyle support.
